There are two main strategies for the combination of PD-1/PD-L1 blockade and cancer vaccines: the preparation of chimeric vaccines, which modify cancer vaccines to have anti-PD-1/PD-L1 effects; and drug combinations, where PD-1/PD-L1 blockers are directly combined with cancer vaccines for tumor treatment. This evidence concerns the gene CD274 and neoplasm.